Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Genitourinary tumours

1198 - A randomized phase III study comparing neoadjuvant chemotherapy followed by concurrent chemo-radiotherapy with concurrent chemo-radiotherapy in Asian-Indian (South Asian) population with muscle invasive bladder cancer


19 Dec 2015


Genitourinary tumours


Shankar Jakhar


Annals of Oncology (2015) 26 (suppl_9): 71-79. 10.1093/annonc/mdv524


S.L. Jakhar1, S. Sharma2, G. Singh2, T. Kothari1, N. Sharma1, S.K. Beniwal3, H.S. Kumar1, R. Sinwar1, M. P1

Author affiliations

  • 1 Radiation Oncology, Acharya Tulsi Regional Cancer Treatment & Research Institute, 334003 - Bikaner/IN
  • 2 Radiation Oncology, Acharya Tulsi Cancer Treatment & Research Institut, 334001 - Bikaner/IN
  • 3 Medical Oncology, Acharya Tulsi Regional Cancer Treatment & Research Institute, 334001 - Bikaner/IN


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1198


To find out the bladder presearvation treatment options in early stage muscle invasive urinary bladder carcinoma.


The primary objective was to compare bladder preservation, survival and toxicity in patients with muscle invasive early bladder cancer (cT2-cT4a). The histo-pathologically proved transitional cell cancer patients were randomly enrolled to receive NACT f/b CCRT (n = 146) versus CCRT (n = 163). Patients have received Cisplatin 80-100 mg/m2 intravenously (IV) on day 1,2 in divided doses and Gemcitabin 1000 mg/m2 IV on days 1 and 8 every 21 days for 3 cycles, latter concurrent chemotherapy (RT 60 Gy in 30#) with Cisplatin 80-100 mg/m2 on d1, 2 in divided doses 3 weekly. The CCRT schedule was similar to the both arms. All statistical calculations were performed using SPSS version 20.0 software.


309 patients were enrolled in the study (median age 61 years, 83.5% male, ECOG performance status 0/1 91.6%, 71.5% smokers, Stage II/III 36.9%;63.1%). The 3 year bladder preservation in NACT f/b CCRT arm patients has 62% and in only CCRT have 54% (8% benefit at 3 years). The median PFS was 26.9 months (95% CI; 23.1-30.5) for NACT f/b CCRT versus 23.1 months (95% CI;19-3-25.6) in the CCRT only arm (p = .59). Patients treated with NACT has more grade 2/3 GI and hematological toxicities, but were statistically insignificant.


NACT f/b CCRT was tolerated better with bladder preservation and DFS survival in Asian Indian population.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings